Infusion Care Providers of America

04/11/2021

https://eyewire.news/articles/horizon-therapeutics-to-resupply-market-with-tepezza-for-the-treatment-of-thyroid-eye-disease-ted-beginning-in-april/?utm_content=161251220&utm_medium=social&utm_source=twitter&hss_channel=tw-54968692

03/19/2021

Encouraging news for patients who receive Ocrevus for their MS therapy.

Ocrevus (ocrelizumab) treatment may delay the need for a wheelchair by seven years in patients with primary progressive multiple sclerosis (PPMS), a study reports. This delay, drawn from clinical trial data on treatment- versus placebo-group patients and supported by real-world findings, likely...

03/05/2021

Will we be "seeing" you at NICA's annual meeting?

It’s the moment we’ve all been waiting for... Registration for the annual meeting is officially OPEN! Join us from the comfort of your home on June 25th and Saturday, June 26th for a premier virtual learning and networking opportunity for , , industry stakeholders, , and others with stake in the provider-administered medication market. Attendees, partners, and sponsors can look forward to many exciting presentations and discussions centered around the provider-administered medication industry, networking opportunities, as well as enhanced meeting features specific to the virtual environment. Registration will fill up quickly, so do not miss your chance to save your spot! Register here: http://bit.ly/2PfnUep

02/26/2021

Diagnosed with severe persistent asthma and wondering how a biologic like Xolair can work for you? Read below:

Official answer: Free serum IgE levels are decreased within an hour of Xolair administration. However it may take several months for...

02/10/2021

Did you know Dupixent, often prescribed for severe persistent asthma also has a second indication? Find out more about atopic dermatitis and how Dupixent can help.

You or your loved one’s eczema could be atopic dermatitis, and might be uncontrolled despite treatment with topical prescription treatments.

02/04/2021

People living with neuromyelitis optica spectrum disorder (NMOSD) experience debilitating symptoms, including blindness, muscle weakness and paralysis. ICPA offers two treatments for this rare disease, Soliris and Uplinza.

NORD gratefully acknowledges Brian Weinshenker, MD, FRCP(C), Professor of Neurology, Mayo Clinic, for assistance in the preparation of this report.

02/01/2021

Our offices will be open, but we’re rescheduling appointments for February 1, 2021.